Aegis’ Buy Rating on Rosetta Genomics May Not Be As Independent As One Might Like

Rosetta Genomics (NASDAQ:ROSG) gapped up 17% in early trading today after Aegis Capital initiated a Buy rating on the company with a target price of $16. Aegis acted as the placement agent for the last four of Rosetta’s public offerings, the most recent of which (early August), granted the investment banking firm options for 825,000 shares of common stock. While this kind of investment banking compensation is not uncommon, and may not necessarily negate a positive analysis, investors should take note of the potential conflict of interest related to this report. (more…)